Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Collagenase ointment for cutaneous sclerosis in systemic scleroderma
IRCT20140624018210N11Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Jan 2022
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of collagenase clostridium histolyticum in systemic sclerosis (SSc), sponsored by Iran University of Medical Sciences. Primary endpoints: Qualitative and quantitative intensity of scleroderma, Facial wrinkle severity and mouth opening and 3 more. Started Jan 2022; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on IRCT20140624018210N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140624018210N11.